NRX Pharmaceuticals Inc. (NASDAQ: NRXP) and its wholly-owned subsidiary, HOPE Therapeutics, Inc., have announced the signing of a definitive agreement to acquire the Kadima Neuropsychiatry Institute, located in La Jolla, CA. This acquisition is set to form the foundation for the HOPE Network of Interventional Psychiatry Clinics. Kadima, renowned for its pioneering work in CNS and psychedelic research, will serve as the clinical model for HOPE's treatment offerings across the nation. Dr. David Feifel, a distinguished figure in interventional psychiatry, will join HOPE as the Chief Medical Innovation Officer following the acquisition's closure. The transaction, expected to enhance revenue and EBITDA for both NRx and HOPE, is subject to standard closing conditions and finalization of financing. Further details will be disclosed in due course.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。